Review

B Cell Metabolism: An Understudied Opportunity to Improve Immune Therapy in Autoimmune Type 1 Diabetes

Christopher S. Wilson 1, Daniel J. Moore 1,2,*

1 Department of Pediatrics, Ian Burr Division of Endocrinology and Diabetes, Vanderbilt University Medical Center, Nashville, TN 37232, USA
2 Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232, USA
* Correspondence: Daniel J. Moore, Email: daniel.moore@vanderbilt.edu; Tel.: +1-615-322-7427; Fax: +1-617-724-7165.

ABSTRACT

Although B lymphocytes are a key cell type that drives type 1 diabetes (T1D), therapeutic targeting of these cells has not ameliorated disease, and it has been impossible to eliminate autoantibody production clinically once it begins. This challenge indicates a need for further dissection of the cellular processes responsible for the development and activation of autoreactive B cells in T1D. Review of the literature in T1D and other autoimmune and hematopoietic diseases indicates that cellular metabolism contributes significantly to lymphocyte development and fate. Unfortunately, little is known about the normal metabolism of B cells and even less is known about the metabolism of B cells in T1D other than what can be inferred from other immune processes. Clues derived from the literature suggest B cell metabolism in T1D is altered including potential differences in OXPHOS, glucose metabolism, fatty-acid metabolism, and reactive-oxygen species stress response. Future research should dissect the metabolic processes at play in autoreactive B cells in T1D. Once understood, B cell metabolism will become a promising target to use in conjunction with current clinical therapies in T1D. Additionally, metabolic changes in B cells may serve as a reliable biomarker for predicting the responsiveness of patients to these immune therapies.

KEYWORDS: autoimmunity; B lymphocyte; type 1 diabetes; development; selection; activation; immune therapy; metabolism; immunoglobulin; autoantibody

INTRODUCTION

Lymphocytes are subject to regulation by intrinsic and extrinsic metabolic parameters. While the metabolism of T cells is well described and has been targeted in pre-clinical models to impact immunity, the metabolism-dependent regulation of B lymphocytes (B cells) is less well understood [1–6]. At baseline, naïve B cells have very little metabolic
activity, a condition that may be important for preventing improper activation of these cells. Indeed, at rest, B cells possess decreased mitochondrial numbers compared to T cells and may possess the least amount of mitochondria among the hematopoietic lineage [7,8]. Upon stimulation B cells increase oxidative phosphorylation, glucose uptake, the citric acid cycle (TCA), and nucleotide biosynthesis [7]. Early work indicated that glucose utilization is important for activation and survival of B cells, similar to their T cell counterparts. While the fate of this glucose was thought to be glycolysis, a new study indicates that the glucose may be utilized for nucleotide biosynthesis over glycolysis [7,9,10]. Contrasting with earlier research, this paper indicates glucose restriction, but not complete removal, did not impact initial B cell activation and proliferation. However, other studies have indicated glucose does limit the capacity for B cells to form germinal centers and produced class-switched antibodies [4,7]. As B cells have multiple functions besides antibody production, it will be important to determine what role glucose plays in antigen capture, presentation, trafficking and survival in addition to B cell activation, expansion, and antibody production.

These properties make B cells unique compared to T cells when evaluating pathways and targets for metabolic modulation of immune function and indicate a need for specific understanding of B cell metabolism to advance immune therapies. Indeed, studies in T cells have begun to elucidate the metabolic parameters that are important for T effector and T regulatory function, but a similar paradigm has not been established in B cells [1].

This review discusses the role of immune metabolism in B cells in autoimmune disease, with a focus on type 1 diabetes (T1D). Although the autoimmune pathology in T1D is driven by T cells, B cells are critical for autoreactive T cell activation making the function of B cells a critical node in disease pathogenesis [11–16]. Attesting further to the central role of B cells in disease, anti-islet autoantibodies have long been recognized as the signature of impending and new-onset disease. The presence of these autoantibodies is now a diagnostic criterion of T1D well in advance of the appearance of clinical hyperglycemia [17]. Clinically, targeted B cell depletion has delayed loss of insulin production in patients with new-onset disease, but unfortunately disease progression returns once B cells repopulate [12,15,18]. Little is known about the B cell intrinsic metabolic processes that drive autoimmunity in T1D, and it has not been considered whether metabolic abnormalities play a role in the reemergence of beta cell destruction after B cell directed therapy. This review will examine the metabolic regulation of normal B cell development and activation, review evidence suggesting dysmetabolic features of B cells in T1D, and highlight opportunities for metabolic interventions to regulate the B cell response to halt disease progression.
NORMAL B CELL DEVELOPMENT AND ACTIVATION IN RELATION TO METABOLISM

B cell development begins in the bone marrow, where approximately 70% of B lymphocytes generated possess an autoreactive specificity [19]. The detection of autoreactive Ig receptor expression triggers either receptor editing or deletion; cells surviving these initial selection steps emerge to the spleen to complete development. At maturation, approximately 25% of the naïve mature B cell population demonstrates hallmarks of receptor editing, indicating replacement of autoreactive receptors with protective immunoglobulins during development to permit continued cell survival [20]. Autoreactive cells that persist after these successive steps in development are thought to undergo anergy in healthy people, rendering them nonresponsive to their cognate antigen [20]. B cells that display non-autoreactive specificities become naïve cells and will activate following antigen encounter leading to production of antibodies of varying affinity and class, depending on the context. Throughout these stages of development and activation, B cell metabolism varies to adapt to the individual metabolic need of each stage. Overall the metabolic requirements of B cells and the metabolic influences on B cell development and activation are poorly understood. Understanding these differences will be important in determining how to influence B cell development and activation and may become part of targeted strategies to prevent and reverse autoimmune disease.

Early B Cell Development Is Marked by Metabolic Requirements for Proliferation

B cells begin their life in the bone marrow, arising from hematopoietic stem cells before entering the common lymphoid progenitor compartment. The pre-pro B cell represents the earliest stage of B cell commitment and is marked by the expression of Ikaros, PU.1, E2A, EBF-1, and Pax-5 [21]. These cells do not express recombinase-activating gene (RAG) and thus possess both the heavy and light immunoglobulin chain (IgH and IgL) gene loci in their germline configurations. The metabolic demands of these cells remain mostly unknown but are likely dependent on IL-7 signaling acting through both STAT and Akt-dependent pathways. While little is understood about the metabolic processes, pre-pro B cells should possess a significant metabolic demand due to their rapid proliferation.

These cells migrate towards their developmental niches within the bone marrow due to CXCL12 chemokine signaling and expression of CXCR4, where they develop into large pro-B cells [22]. These cells are acutely dependent on IL-7 to prevent apoptosis and induce proliferation [22,23]. At this stage, pro-B cells utilize glycolysis; studies in T cells suggest this utilization is most likely due to the action of IL-7 on the Akt pathway. Additionally, B cells at this stage enhance oxidative phosphorylation [24–
26]. Phosphorylation of c-Abl peaks during this time in B cell development indicating an important role for c-Abl in this developmental stage [27]. Other studies have demonstrated that c-Abl activation increases glucose uptake in B cell cancers, suggesting it may also do so here to help developing B cells avoid apoptosis [28]. At the end of the pro-B cell stage, Rag1 and 2 are activated to allow for the recombination of V, D, and J regions of the heavy chain locus. Successful recombination of the heavy chain locus leads to surface expression of the heavy chain paired with a surrogate light chain forming the pre-BCR. This event marks the transition from pro- to pre-B cell, concomitant with a loss of IL-7 sensitivity [24,29]. The change from IL-7R dependency to pre-BCR signaling represents the first step in a developmental switch that places much of the metabolic signaling downstream of the BCR [30–33].

Establishment of the pre-BCR facilitates the ability of spleen tyrosine kinase (Syk) to signal through PI3K and Erk pathways allowing large Pre-B cells to undergo a proliferative burst associated with metabolic upregulation of both glucose uptake and mitochondrial activity [30,33–36]. After this initial proliferative burst, the cells enter the small-pre-B stage marked by reactivation of Rag 1 and 2 to allow VJ recombination of the light chain gene locus [37]. Studies in pre-B acute lymphoblastic leukemia (ALL) suggest that Pax5, EBF1, and Ikaros may be responsible for downregulation of metabolic genes to pause the cell cycle and allow for proper recombination of the light chain to occur [38]. Additionally, Foxo1, a gene activated by metabolic deprivation, is essential for activation of Rag1/2, further suggesting robust metabolic changes may occur at this stage [23,39,40]. Experimental observations demonstrate a downregulation of glucose uptake and decreases in mitochondrial membrane potential and ROS production at this stage [33]. While there is an overall reduction in energy consumption, these cells seem to favor OXPHOS, but the preferential metabolic substrate remains to be determined.

Immature B cells are subject to selective pressure if they encounter their cognate antigen [19]. If the initial heavy and light chain pairing is directed against a self-antigen, then antigen encounter will trigger the immature B cell to recombine its second light chain locus and express a newly paired BCR [41]. If this BCR is also autoreactive, then the cell will undergo apoptosis resulting in negative selection [42]. Studies of the WEHI-231 immature B cell line indicate this process is regulated in part by breakdown of the mitochondrial membrane potential [43]. While calcium signaling perpetuated from the BCR leads to activation of caspases to mediate cell death, changes in mitochondria precede the death of B cells induced by BCR signaling at this stage and may further exacerbate changes in intracellular calcium handling [42,44–46]. The mechanism of loss of mitochondrial membrane potential and its metabolic consequences in B cells remains poorly understood but may be regulated by the Bcl-2 family of proteins leading to changes in ion pores in the mitochondria [44–49].
Another intriguing mechanism of mitochondrial collapse in B cells is the accumulation of arachidonic acid or ceramide in the mitochondria due to activation of mitochondrial phospholipase A2 (PLA2) [43,50]. The change in the lipid profile in the mitochondrial membrane can alter membrane integrity and permeability, providing a link between lipid metabolism and B cell selection. Like the preceding stage, immature B cells are metabolically quiescent and the primary metabolic substrate that is utilized is undefined [51].

**NAÏVE SPLENIC B CELLS ARE MAINTAINED IN A REDUCED METABOLIC STATE VIA THE LKB1/AMPKA PATHWAY**

After completion of these bone marrow developmental stages, B cells exit the bone marrow and enter the spleen, where they are subjected to continued negative selection in the transitional B cell compartment before entering the mature compartments [52]. Virtually nothing is known about the metabolic requirement of these transitional B cells and how metabolic changes may impact negative selection, although this is the key stage that prevents maturation of autoreactive B lymphocytes. Once matured, B cells are composed of two main compartments, B1 (often referred to as peritoneal B cells) and B2 (traditional splenic B cells) [53]. B1 B cells are found in small quantities in the spleen and are mostly localized to the peritoneal cavity; it is unclear whether these cells arise via the same developmental pathway as B2 B cells [54,55]. These cells produce non-induced IgMs often against polysaccharide targets [56]. This activity is most likely metabolically demanding, and thus these cells demonstrate enhanced metabolism and a dependence on glycolysis [56]. B2 B cells demonstrate metabolic inertness as compared to their B1 counterparts, demonstrating utilization of fatty-acid (FA) as their oxidative fuel source [57]. There appears to be a reduction in the ratio of ATP to AMP indicating resting B cells are in a state of energy deprivation that is thought to be maintained via LKB1/AMPKa signaling axis [38,58]. B2 B cells are divided into two classes, marginal zone and follicular zone B cells [53]. The follicular zone B cells are responsible for producing high-affinity class-switched antibodies upon activation while the marginal zone B cell produces natural antibodies in a T-independent manner much like B1 B cells, but thus far no differences have been demonstrated in their metabolic needs or activity [59]. While no overt differences in metabolism have been defined between these two cell subsets, studies of human transitional B cells indicate that the maturation to follicular zone B cells induces downregulation of the mTOR/Akt signaling pathway as well as other metabolic pathways [60]. Marginal zone B cells seem to be reliant upon the action of mTOR/Akt signaling as genetic loss of this pathway leads to a reduction in this cell type [61–64]. Additionally, marginal zone B cells require Notch2 signaling to differentiate [65,66]. In activated T cells Notch signaling has a complex interaction with glutamine metabolism in the control of IL-2 production [67]. Notch signaling may provide the capacity...
to modulate function in the case of limited nutrients, and this interaction may distinguish marginal zone and follicular B cell function, but further investigation is needed.

**B Cell Activation Leads to Increased Metabolism and Generation of ROS for Proper B Cell Function**

Upon activation, B cells upregulate metabolic processes, a function dependent on the action of c-Myc [57]. A recent study has clarified the metabolic processes that occur during B cell activation and how they differ from T cell activation. An unbiased approach utilizing RNA seq and analysis of mitochondrial morphology revealed that, upon activation by their cognate antigen or via TLR signaling through LPS, B cells begin to upregulate OXPHOS and extensively remodel the mitochondria to support increased ATP production [7]. Surprisingly, tracking of a glucose isotopomer revealed that the majority of glucose was shunted towards the tricarboxylic acid cycle (TCA) and towards the pentose phosphate pathway for ribonucleotide synthesis, but not glycolysis [7]. Corroborating these results, glucose restriction did not impact the activation or proliferation of B cells while inhibiting OXPHOS or glutamine metabolism severely crippled B cell activation [7]. Previous work on B cell activation indicated an increase in glycolysis in activated B cells [57]. Indeed, one of the major functions of B cells, antibody production, depends on proper glycosylation of the produced immunoglobulins to sustain structural stability, promote immune regulation, and bind Fc receptors [68–71]. The substrates utilized for glycosylation are often shared with energy-producing glycolytic pathways, indicating a greater need for flexible glucose metabolism in relation to antibody production and function and the potential that changes in these pathways could alter B cell effector or regulatory function [72,73].

**Anergic, Autoreactive B Cells Cannot Upregulate Metabolism after Stimulation**

Some autoreactive B cells escape negative selection during development and persist to maturity. In healthy individuals these cells are speculated to be continuously occupied with self-antigen [74]. This tonic signaling is thought to render these cells “anergic”, a condition in which these cells are unresponsive to further stimulation and thus unable to mount an effective response against their cognate antigen [74]. To recapitulate and analyze the metabolism of an anergic B cell, researchers studied B cells from double transgenic mice that expressed both anti-HEL B cells and the HEL antigen. B cells from these mice demonstrated metabolic impairment in both glycolysis and OXPHOS compared to B cells from mice possessing only the BCR in the absence of antigen [57]. This observation indicates that anergy depends, in part, on restricting metabolism to prevent activation. The signaling pathways and timing of signaling that drives and maintains metabolic anergy in B cells still needs
to be dissected and it is not known whether enforcing limited access to nutrients could enhance anergy induction to address autoreactive cell activation.

Summary of Normal B Cell Metabolism and Caveats to B Cell Metabolism Research

This synopsis of normal B cell metabolism sets the framework for dissecting the ways in which B cell metabolism interacts with B cell development and selection, and how metabolism may be important for the development of B cell driven autoimmune disorders. It is worth noting that the isolation of distinct pro-B cells and pre-B cells in sufficient numbers for metabolic analysis is difficult in wild-type mice. Many of the studies that define the metabolic state of these cells are carried out in knockout mice that develop blocks in B cell development due to loss of critical transcription factors. As B cell development is a dynamic process and driven by the availability of homeostatic factors, it is possible that a block in B cell development may have unintended consequences on B cell metabolism. In mature B cells, as in T cells, many of the metabolic requirements have been determined by utilizing compounds that block metabolic pathways in an ex vivo system. These inquiries suffer from both the lack of specificity (i.e., the compounds have off-target effects that impair other aspects of cell function) and the cells are tested in a condition of hyper-nutrition that may not recapitulate the in vivo reality. Nonetheless, these are the best data available for B cell metabolism and indicate the need for more research into the metabolic underpinnings of B cell development and function. A summary of what is currently known about B cell metabolism across development is outlined in Figure 1.

THE METABOLIC STATE OF B CELLS IN T1D

Defects in LKB1/Ampka May Alter Mitochondrial Dynamics in B Cells in T1D

Scant data exists for the metabolic state of mature naïve B cells in T1D. The healthy resting B cell seems to be in a state of energy deprivation as illustrated by a decrease in the amount of ATP and an increase in the amount of cellular AMP. This imbalance of the AMP to ATP ratio indicates increased activity in the LKB1/AMPKa pathway in B cells [38,58]. The result of this seemingly chronic activation of LKB1/AMPKa is apparent in the reduced number of mitochondria relative to other cells of the hematopoietic lineage [8,75]. These small, fused mitochondria are relatively inert and do not produce significant levels of ATP [7]. Interestingly, LKB1 opposes the activity of NF-kB, a pathway that is upregulated in B cells in the NOD (non-obese diabetic) mouse, the primary preclinical model of T1D, and thought to contribute to T1D pathophysiology [76,77]. Dysregulation of the LKB1/AMPKa pathway could lead to increased mitochondrial mass in T1D and leave B cells poised for...
metabolic priming with even suboptimal signaling. Clinically, targeting this abnormal process with metformin could potentially correct LKB1/AMPKa signaling and reduce NF-kB signaling and warrants further investigation (see Figure 4).

Figure 1. The utilization of oxidative phosphorylation and glycolysis varies throughout the development of B cells. Early in B cell development (pro-B), the metabolic demand is high as developing B cells rapidly proliferate. In this stage both glycolysis and oxidative phosphorylation are increased, largely due to the action of IL-7 signaling. The large pre-B cell has enhanced glycolysis and OXPHOS, which may be due to an initial signaling burst from the pre-BCR. Downregulation of the pre-BCR to allow for recombination of the light chain blunts metabolism, a trait that is carried until reactivation of the B cell. Once a complete BCR is expressed, the immature B cell possesses reduced metabolism and may be dependent on fatty-acids as its primary metabolic substrate. Naïve B2 B cells maintain reduced metabolism and dependence on fatty-acid metabolism. Individual metabolism of B2 B cell subsets including the follicular and marginal zone remains unknown. B1 B cells, which reside primarily in the peritoneal cavity, depend largely on glycolysis for survival. Upon activation, B cells upregulate glucose uptake and remodel their mitochondria. There are conflicting reports on whether glucose is utilized in glycolysis or for the production of nucleotides. This disparity may be due to the changing role of glycolysis between early and late B cell activation and should be clarified by further studies. The amino acid glutamine is the primary metabolite utilized in OXPHOS for B cell activation and proliferation.

T1D B Cells Have Increased Levels of Lipid Scavenger CD36
Indicating Enhanced FA Metabolism

While oxidative metabolism is important for activated and naïve resting B cells alike, naïve B cells seem to rely on FA as their main fuel
source [57]. Dyslipidemia is a characteristic of T1D, but it is generally thought to be a result of hyperglycemia and insulin deficiency after disease onset [78,79]. However, studies of the NOD mouse metabolome in pre-diabetic mice indicated changes in the lipid profiles including increases in triglycerides in mice that progress to diabetes compared to those that are protected [80]. By comparison, B cells in high-fat diet fed mice demonstrate general immune activation, produce more IgG and less IgM, and increase whole body insulin resistance, indicating a role for altered lipid metabolism in immune activity that corresponds with features of the NOD mouse [81]. In NOD mice our lab demonstrated that B cells possess enhanced expression of CD36, a fatty acid translocase (FAT) [82]. Upregulation of lipid scavenger CD36 correlated with an increased propensity for B cells to take up BODIPY-labeled linoleic acid (unpublished data). This increased affinity for lipid metabolites via upregulation of lipid scavenger CD36 may impact the activity of B cells. While fatty-acids are important for B cell metabolism, it remains unknown the consequence of enhanced uptake of fatty-acids by B cell-expressed CD36, which has the highest affinity for oxidized-low density lipoproteins (oxLDL) [83]. Uptake of oxLDLs enhances inflammation in many cell types, including B cells [84]. Interestingly, oxLDLs are often found complexed with immunoglobulins [85]. Normally, binding of circulating immunoglobulins to Fc-receptors on B cells inhibits these cells by activation of SHIP [86,87]. When oxLDLs are complexed with immunoglobulins and internalized, this process activates the NLRp3 inflammasome in bone marrow derived dendritic cells, a process dependent on TLR4, CD36 and Fcgamma receptor signaling [85,88]. This interaction could lead to escape of B cells from IgG mediated inhibition. This observation justifies the need for investigation into the role of circulating nutrients as an environmental trigger in at least some patients with T1D. The role of lipids as an inciting event in humans with T1D is presently unknown but changes in weight gain and growth patterns have recently been associated with diabetes risk [89].

Genes Involved in Regulation of Glucose Metabolism Are Abnormal in T1D

Glucose metabolism is low in naïve cells, but once activated or transformed, B cells utilize glucose largely through the Pentose Phosphate Pathway (PPP) [7]. In naïve B cells the transcription factors Pax5, EBF1, and Ikaros control B cell lineage commitment as well as maintain low glucose flux, presumably by regulating both Glut1 and the insulin receptor [38]. Changes in these critical control elements may change the tempo of progression to type 1 diabetes. One study indicated an allele of Ikaros that is associated with susceptibility to childhood acute lymphoblastic leukemia may protect from T1D [90]. The idea that an allele of a gene that presumably supports enhanced metabolism characteristic of leukemia would slow progression of autoimmunity stands in opposition to common models for the role of T cell metabolism during autoimmunity [6].
Additionally, upregulation of Pax5 predicted faster progression of beta cell destruction in patients with T1D as found in comparison between subjects with rapid loss of insulin production to those who had slower loss [91]. The data indicate that genes that restrict glucose metabolism in B cells may actually be detrimental to T1D disease progression.

Alternatively, evidence suggests that enhanced glucose utilization may also be a characteristic of T1D. During B cell activation, c-Myc ramps up metabolism including glucose uptake and glycolysis [57]. Studies from isolated total leukocytes from prediabetic NOD spleens indicated early changes in metabolic pathways, as compared to healthy control mice. c-Myc was among these upregulated genes [92]. Additionally, c-Myc is upregulated in response to glucocorticoids in T cells from NOD mice, thus preventing apoptosis through a mechanism that has been related to increasing glycolytic metabolism to subvert apoptosis in other cell types [93,94]. These findings indicate the possibility for altered lymphocyte glucose metabolism in the pathogenesis of T1D. Whether c-Myc plays a role in glucose metabolism in B cells from T1D remains to be seen. These genes and their putative role in B cells in T1D are outlined in Figure 2; given the potential contrasting roles performed by glucose utilization, it remains critical to understand the metabolic demands of B cells throughout normal development and in relation to T1D progression.

While healthy B cells seem to favor OXPHOS and nucleotide biosynthesis as downstream products of glucose metabolism, excess glucose uptake in T1D B cells may feed into glycolysis. The nutrient excess may lead to cellular stress and inappropriate B cell activation. As n-glycosylation of proteins is integrally linked to glucose metabolism, changes in glucose metabolism may drive aberrant glycosylation patterns that could hinder appropriate cell-cell communication and alter antibody production or function. Naturally-occurring IgMs have recently been determined to maintain immune regulation, and this activity has been linked to its glycosylation pattern [95–101]. Abnormal glucose utilization could lead to improper glycosylation of IgM and loss of its regulatory capacity. We have recently determined that IgM from NOD mice do not possess the same capacity to properly regulate B cell homeostasis, Treg function, and prevention of T1D as compared to healthy control animals [102]. How IgM glycosylation drives this failure in immune regulation and how it can be corrected remains to be determined. Additional research will need to be conducted to understand the developmental stages during which abnormal metabolism acts to accelerate B cell pathology in T1D.
Figure 2. Genes involved in the regulation of glucose in B cells. (A) The genes and related pathways outlined here have been associated with glucose regulation in B cells. Pax5 and Ikaros oppose glycolysis and enforce OXPHOS through transcriptional control of genes NR3C1, TXNIP, CNR2 to restrict cellular nutrients and activate APMKα at multiple steps of B cell development. In normal B cell activation, c-Myc regulates the expression of multiple proteins involved in glycolysis including glucose transporter 1 (Glut1), hexokinase, phosphofructokinase (PFK), and lactate dehydrogenase A (LDHA). (B) Studies in humans indicate that an allele of Ikaros (IKZF1) that is associated with oncogenesis and potentially enhances glycolysis offers protection against T1D. c-Myc (MYC) activity is elevated in mice with T1D and may drive enhanced glycolysis, which is potentially harmful for immune regulation. Increased Pax5 (PAX5) expression in humans leads to enhanced beta cell loss. This gene list and putative effects on disease progression indicate a need to reconcile the potential differences in B cells in murine models and humans. Future studies should define what developmental stage these genes act on to induce metabolic derangement in B cells in T1D.

The Antioxidant Response in B Cells in T1D Is Heightened

Along with changes in metabolism, increased oxidative metabolites were found in the circulation of NOD mice that rapidly progressed to disease indicating increased oxidative stress as suggested in the previous section [80]. B cell receptor mediated production of ROS is important for proper activation and function of B cells [103,104]. This ROS modulates signaling pathways by transiently inhibiting phosphatases to enhance and prolong signaling (outlined in Figure 3A) [105]. While increased ROS production may lead to aberrant immune activation and autoimmunity, operating under continuous extrinsic and intrinsic oxidative stress could lead to cellular apoptosis in immune cells unless a strong antioxidant system is in place.

Although B cells require ROS for full activation, increased ROS production drives apoptosis in certain stages of immature B cells [106]. An excessive antioxidant response could lead to the survival of autoreactive B cells that are receiving antigen stimulation during steps in negative selection. An increased antioxidant response, as we have observed in NOD B cells, would potentially support the production of autoantibodies in T1D and the perpetuation of an autoreactive cell population that might not normally produce a long-lived antibody response [107]. This initial
investigation indicated that this antioxidant capacity was likely due to the action of the superoxide dismutase system (SOD1 and SOD2) and not through the glutathione peroxidase (GPx) [107]. This enhanced oxidative protection may be an intrinsic characteristic of all B cells in NOD mice or may be a consequence of some stage of negative selection in which only those cells with the greatest capacity to resist ROS-induced apoptosis survive.

Figure 3. Reactive-oxygen species (ROS) metabolism is important in many aspects of B cell function. ROS enhances the immune response and causes direct damage to pathogens and other cells that lack antioxidant capacity. Intracellular ROS modulates B cell function in many ways. (A) Upon B cell activation, BCR signaling triggers ROS production via the mitochondria and NADPH oxidase 1 (NOX1) complex. This ROS reversibly oxidizes tyrosine phosphatases to limit their ability to dephosphorylate target kinases. This action prolongs and enhances BCR signaling [104,108]. (B) Antigen internalization and presentation is an essential function of B cells and is modulated by production of ROS via NOX1. This production is key for the ability of antigens internalized via the BCR to be presented on the cell surfaces via Major-histocompatibility complex II (MHCII). Interestingly, ROS does not impact the presentation of intracellular derived antigens [103]. (C) After activation ROS opposes the capacity of B cells to secrete immunoglobulin. Nrf2 promotes IgM secretion by increasing antioxidant genes to oppose ROS [109]. (D) Both ROS and antioxidants that emerges from B cells impact bystander cells. B cells that present antigen to Tregs could transfer ROS to Tregs thus enhancing Tregs via the action of SENP3 and Bach2 [110]. Conversely, a B cell with enhanced antioxidant capacity may prevent ROS-mediated activation of SENP3 and thus inhibit Tregs. The action of B cells may also mediate tissue protection in cell types sensitive to ROS, like beta cells. Under certain circumstances B cells can upregulate antioxidant capacity that can be transferred to the extracellular space (green dots). This transfer prevents degradation of ROS-sensitive beta cell transcription factor Mafa and loss of beta cell identity. Activated B cells could also produce ROS that is deleterious to beta cell health.
Increased antioxidant capacity could also alter the antigen presenting role of B cells in T1D [103]. Many studies indicate that B-T cell interaction perpetuates autoimmunity [111]. B cells communicate with the T cell at the immune synapse via the Major-Histocompatibility Complex through presentation of antigen as well as accessory molecules, leading to mutual activation. ROS is also produced at this immune synapse and has significant consequences for T cell activation by inhibiting phosphatases and enhancing and prolonging intracellular signaling [112]. Whether this ROS can be impacted by antioxidant capacity of the individual APC is less well understood. Interestingly, in vitro studies indicate that ROS production by macrophages induces new Tregs in a ROS-dependent manner [113]. Other studies indicate that ROS stabilizes Foxp3 expression via SUMO-specific protease 3 (Senp3) activation and retention of Bach2 in the nucleus thus suppressing expression of T effector genes and maintaining Treg stability (Figure 3D) [110]. The presence of B cells with enhanced antioxidant capacity may reduce the amount of ROS that a docked Treg sees thus preventing stabilization of Foxp3 leading to loss of Treg stability or prevention of the induction of new Tregs. This metabolic counter-regulation may disrupt immune regulation in T1D. The many putative roles of ROS in B cells are outlined in Figure 3.

THERAPEUTIC TARGETING OF B CELLS IN T1D PROVIDE CLUES TO METABOLIC ALTERATIONS

While there is very little direct evidence defining B cell metabolism in T1D, the response of B lymphocytes in T1D to treatment with immune therapies may offer clues to their metabolic regulation. Two therapeutics, anti-CD20 (Rituximab) and Imatinib (Gleevec), have been studied in recent onset T1D and both have been studied extensively in malignant hematopoietic disease where there are known metabolic requirements and consequences among the targeted cells that dictate treatment efficacy. Thus, the effectiveness or lack thereof in T1D may provide indirect insight into the metabolic state of B cells in T1D.

Anti-CD20 is the only B cell targeting therapeutic tested clinically in T1D to date [12,114]. In human clinical trials in new onset T1D, there was moderate protection from beta cell loss but beta cell loss resumed soon after therapy was discontinued [114]. This resumption was linked back to a reemergence of autoreactive specificities after therapy, as well as a loss of CD20 in B cells that infiltrated the pancreas [15,18]. This change in anti-CD20 expression was linked to activation induced by CD40-CD40L interactions, which targets the PI3K/Akt signaling pathway [115,116].

Recently, c-Abl inhibitor Gleevec (imatinib mesylate) was found to reverse T1D in NOD mice [117]. The cellular and molecular mechanisms that provide this reversal are not well understood, although several studies have related it to a reduction of cellular stress at the level of the beta cell [118–120]. Work from our lab links this back to an increase in the antioxidant response in B lymphocytes that is passed on to the
extracellular environment [107]. Enhanced B cell redox restored ROS-sensitive Mafa in beta cells leading to improved insulin secretion and restoration of euglycemia but only when B cells were present [107]. This interaction illustrates the potential for excessive antioxidant metabolism among B cells in T1D. This antioxidant phenotype is similar to that seen in the response of hematopoietic cancers that develop resistance to these cancer therapeutics [121,122]. Taken together these data indicate B cells in T1D may be uniquely adapted to handle metabolic stress, which in turn may provide resistance to therapy or tissue protection depending on the context. This adaptation may also underlie the development and survival of the autoreactive cells that initiate disease by protecting them from negative selection.

WHAT DO WE TARGET IN B CELL METABOLISM IN T1D?

B cells may be targeted to alter development, to prevent activation, to prevent B cell-T cell interactions and antigen presentation, or to modify their metabolic state to allow for favorable functions or more successful immune depletion in combination with other B cell therapeutics. Current research suggests that the metabolic requirements of T and B cells are different, which provides an opportunity to target these subsets specifically but also could limit the impact of metabolic therapies given the dependence of disease on both cell types. Additionally, poor subset discrimination between regulatory and effector B cell subtypes prevents the elegant dissection of metabolic requirements for regulation versus effector function as has been achieved in T cells. When implementing metabolic therapies, unintended consequences could result on both regulatory and effector T and B cells, especially in diseases in which the interplay of these cell types have an important role like T1D.

Virtually no research exists that directly assesses the metabolic state of B cells in T1D in mice or in humans. Analysis of the available evidence as presented in this review suggest that multiple metabolic defects in glucose uptake, mitochondrial dynamics, ROS metabolism, enhanced expression of lipid scavenger CD36, and enhanced fatty-acid uptake could contribute to abnormal B cell development, activation, or survival in T1D (Summarized in Figure 4). Additional research needs to be carried out to determine whether targeting these metabolic pathways could normalize B cell development, prevent survival of autoreactive B cells, inhibit auto-antigen presentation, or induce beta cell protection. The fact that metabolism plays an integral role in all of these pathways highlights the importance of understanding B cell metabolism in T1D.
Figure 4. Predicted metabolic abnormalities in B cells in T1D encompass multiple pathways with consequences on B cell function. Enhanced NF-KB signaling in NOD B cells may oppose the LKB1/AMPKα pathway, leading to increased mitochondrial mass and priming the cell to respond robustly to myriad metabolites. As B cell activation is dependent on mitochondrial remodeling, enhanced mitochondrial mass (“pre-activation”) could increase the metabolic fitness of autoreactive B cells and allow them to effectively generate ATP in areas of low nutrients. Enhanced c-Myc activity has been identified in lymphocytes from NOD mice. As c-Myc regulates glucose metabolism, an increase in c-Myc activity in B cells could increase Glut1 expression and glucose trafficking driving enhanced oxidative phosphorylation of glucose and glycolysis. This change could alter B cell function through enhanced metabolic fitness as well as alter the glycosylation patterns on immunoglobulins and cell surface proteins. B cells in NOD mice express enhanced lipid-scavenger CD36. This enhanced expression could increase utilization of fatty-acids, the main substrate of naïve B cells, thus improving survival. Additionally, CD36 capture of OXLDL immune-complexes could activate the NLRP3 inflammasome. Finally, increases in metabolism increase ROS production, which could be detrimental to B cell survival and function. T1D B cells seem to possess enhanced antioxidant capacity to protect against ROS. Additionally, this property has been demonstrated to offer tissue protection by scavenging ROS in the islet-microenvironment and protecting ROS-sensitive transcription factors but may at the same time diminish Tregs, pointing to a careful balance needed for any metabolic therapy.

While there is much more work to be done on the basic metabolic pathways in autoreactive B cells, there are emerging opportunities to advance understanding of immune metabolism in the clinical space. As suggested above, it may be readily hypothesized that treatment with anti-CD20 or imatinib could have metabolic consequences on B cells that may dictate the response to therapy, and this hypothesis could be explored in clinical trial samples. Likewise, therapies depleting T cells or other cell types could alter the types of stimulation that B cells receive which may impact their metabolism and change their sensitivity to metabolic therapy.
Understanding the metabolic landscape induced by immune therapy is an outstanding opportunity to improve future approaches to the treatment of T1D. At the same time, understanding how immune metabolism changes across cell subsets as people progress towards type 1 diabetes, such as in the T1D TrialNet, will be invaluable to understanding the impact of immune metabolism on autoimmunity and in identifying future treatments. As it is becoming clear that metabolism is intricately complexed to the effector function in hematopoietic cells, it needs to be addressed whether cellular metabolism will provide a more predictive biomarker of disease progression and therapeutic responses. Despite the many remaining unknowns, there are clear clues to the role of metabolism in B cells in T1D that present an opportunity awaiting further exploration and implementation. Figure 5 summarizes the putative metabolic abnormalities in B cells in T1D, the potential consequences, and the therapeutic options available to augment these processes. As data become available in T1D we anticipate that future approaches will specifically target these metabolic pathways directly for treatment and will use these metabolic readouts to predict responsiveness to immune therapies in T1D clinical trials.

**Figure 5. The putative differences in B cell metabolism in T1D, their effects, and potential therapeutic opportunities.** This figure illustrates predicted differences in B cell metabolism in T1D, their consequence on normal B cell function, and the potential therapeutic interventions that may alter these metabolic parameters to protect from disease.

**AUTHOR CONTRIBUTIONS**

CSW and DJM researched, wrote, and edited this review.

**CONFLICTS OF INTEREST**

The authors declare no conflict of interest
FUNDING

DJM was supported by a Career Development Award from the JDRF and by the Thomas J. Beaton Jr Foundation Grant #2019-016.

ACKNOWLEDGMENTS

Figures were created with Biorender.com.

REFERENCES

1. van der Windt GJW, Pearce EL. Metabolic switching and fuel choice during T-cell differentiation and memory development. Immunol Rev. 2012;249(1):27-42.
2. Raud B, Roy DG, Divakaruni AS, Tarasenko TN, Franke R, Ma EH, et al. Etomoxir Actions on Regulatory and Memory T Cells Are Independent of Cpt1a-Mediated Fatty Acid Oxidation. Cell Metab. 2018;28(3):504-15.e7.
3. Lee C-F, Lo Y-C, Cheng C-H, Furtmüller GJ, Oh B, Andrade-Oliveira V, et al. Preventing Allograft Rejection by Targeting Immune Metabolism. Cell Rep. 2015;13(4):760-70.
4. Palmer CS, Ostrowski M, Balderson B, Christian N, Crowe SM. Glucose metabolism regulates T cell activation, differentiation, and functions. Front Immunol. 2015;6:1.
5. Johnson MO, Wolf MM, Madden MZ, Andrejeva G, Sugiura A, Contreras DC, et al. Distinct Regulation of Th17 and Th1 Cell Differentiation by Glutaminase-Dependent Metabolism. Cell. 2018;175(7):1780-95.e19. doi:10.1016/j.cell.2018.10.001
6. Yin Y, Choi S-C, Xu Z, Perry DJ, Seay H, Croker BP, et al. Normalization of CD4+ T cell metabolism reverses lupus. Sci Transl Med. 2015;7(274):274ra18.
7. Waters LR, Ahsan FM, Wolf DM, Shirihai O, Teitell MA. Initial B Cell Activation Induces Metabolic Reprogramming and Mitochondrial Remodeling. iScience. 2018;5:99-109.
8. Iwama Y, Eguchi M. Quantitative evaluation of leukemic mitochondria with a computer-controlled image analyzer. Virchows Arch B. 1986;51(1):375-84.
9. Doughty CA, Bleiman BF, Wagner DJ, Dufort FJ, Mataraza JM, Roberts MF, et al. Antigen receptor-mediated changes in glucose metabolism in B lymphocytes: role of phosphatidylinositol 3-kinase signaling in the glycolytic control of growth. Blood. 2006;107(11):4458-65.
10. Dufort FJ, Bleiman BF, Gumina MR, Blair D, Wagner DJ, Roberts MF, et al. Cutting Edge: IL-4-Mediated Protection of Primary B Lymphocytes from Apoptosis via Stat6-Dependent Regulation of Glycolytic Metabolism. J Immunol. 2007;179(8):4953-7.
11. Tian J, Zekzer D, Lu Y, Dang H, Kaufman DL. B cells are crucial for determinant spreading of T cell autoimmunity among beta cell antigens in diabetes-prone nonobese diabetic mice. J Immunol. 2006;176(4):2654-61.
12. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, Becker DJ, Gitelman SE, Goland R, et al. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med. 2009;361:2143-52.
13. Hulbert C, Riseili B, Rojas M, Thomas JW. B cell specificity contributes to the outcome of diabetes in nonobese diabetic mice. J Immunol. 2001;167(10):5535-8.
14. Zekavat G, Rostami SY, Badkerhanian A, Parsons RF, Koeberlein B, Yu M, et al. In Vivo BLYs/BAFF Neutralization Ameliorates Islet-Directed Autoimmunity in Nonobese Diabetic Mice. J Immunol. 2008;181(11):8133-44.
15. Serreze DV, Chapman HD, Niens M, Dunn R, Kehry MR, Driver JP, et al. Loss of intra-islet CD20 expression may complicate efficacy of B-cell-directed type 1 diabetes therapies. Diabetes. 2011;60(11):2914-21.
16. Henry RA, Kendall PL, Thomas JW. Autoantigen-specific B-cell depletion overcomes failed immune tolerance in type 1 diabetes. Diabetes. 2012;61(8):2037-44.
17. Insel RA, Dunne JL, Atkinson MA, Chiang JL, Dabelea D, Gottlieb PA, et al. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care. 2015;38(10):1964-74.
18. Chamberlain N, Massad C, Oe T, Cantaert T, Herold KC, Meffre E. Rituximab does not reset defective early B cell tolerance checkpoints. J Clin Invest. 2016;126(1):1-6.
19. Grandien A, Fucs R, Nobrega A, Andersson J, Coutinho A. Negative selection of multireactive B cell clones in normal adult mice. Eur J Immunol. 1994;24(6):1345-52.
20. Wardemann H, Yurasov S, Schaefer A, Young JW, Meffre E, Nussenzweig MC. Predominant autoantibody production by early human B cell precursors. Science. 2003;301(5638):1374-7.
21. Hagman J, Lukin K. Transcription factors drive B cell development. Curr Opin Immunol. 2006;18(2):127-34.
22. Tokoyoda K, Egawa T, Sugiyama T, Choi B-I, Nagasawa T. Cellular Niches Controlling B Lymphocyte Behavior within Bone Marrow during Development. Immunity. 2004;20(6):707-18.
23. Hedrick SM. The cunning little vixen: Foxo and the cycle of life and death. Nat Immunol. 2009 Oct 23;10(10):1057-63.
24. Milne CD, Paige CJ. IL-7: A key regulator of B lymphopoiesis. Semin Immunol. 2006;18(1):20-30.
25. Wofford JA, Wieman HL, Jacobs SR, Zhao Y, Rathmell JC. IL-7 promotes Glut1 trafficking and glucose uptake via STAT5-mediated activation of Akt to support T-cell survival. Blood. 2008;111(4):2101-11.
26. Kojima H, Kobayashi A, Sakurai D, Kanno Y, Hase H, Takahashi R, et al. Differentiation Stage-Specific Requirement in Hypoxia-Inducible Factor-1α-Regulated Glycolytic Pathway during Murine B Cell Development in Bone Marrow. J Immunol. 2010;184(1):154-63.
27. Brightbill H, Schlissel MS. The effects of c-Abl mutation on developing B cell differentiation and survival. Int Immunol. 2009;21(5):575-85.
28. Martín-Lorenzo A, Auer F, Chan LN, García-Ramírez I, González-Herrero I, Rodríguez-Hernández G, et al. Loss of Pax5 Exploits Sca1-BCR-ABL p190 Susceptibility to Confer the Metabolic Shift Essential for pB-ALL. Cancer Res.
29. Milne CD, Fleming HE, Paige CJ. Frontline: IL-7 does not prevent pro-B/pre-B cell maturation to the immature/sIgM+ stage. Eur J Immunol. 2004;34(10):2647-55.
30. Ochiai K, Maienschein-Cline M, Mandal M, Triggs JR, Bertolino E, Sciammas R, et al. A self-reinforcing regulatory network triggered by limiting IL-7 activates pre-BCR signaling and differentiation. Nat Immunol. 2012;13(3):300-7.
31. Herzog S, Reth M, Jumaa H. Regulation of B-cell proliferation and differentiation by pro-B-cell receptor signalling. Nat Rev Immunol. 2009;9(3):195-205.
32. Hardy RR, Carmack CE, Shinton SA, Kemp JD, Hayakawa K. Resolution and characterization of pro-B and pre-pro-B cell stages in normal mouse bone marrow. J Exp Med. 1991;173(5):1213-25.
33. Stein M, Düttning S, Mougiakakos D, Bösl M, Fritsch K, Reimer D, et al. A defined metabolic state in pre B cells governs B-cell development and is counterbalanced by Swiprosin-2/EFhd1. Cell Death Differ. 2017;24(7):1239-52.
34. Baracho G, Miletic A, Omori S, Cato M, Rickert R. Emergence of the PI3-kinase pathway as a central modulator of normal and aberrant B cell differentiation. Curr Opin Immunol. 2011;23(2):178-83.
35. Schuh W, Meister S, Herrmann K, Bradl H, Jäck H-M. Transcriptome analysis in primary B lymphoid precursors following induction of the pre-B cell receptor. Mol Immunol. 2008;45(2):362-75.
36. Yasuda T, Sanjo H, Pagès G, Kawano Y, Karasuyama H, Pouysségur J, et al. Erk Kinases Link Pre-B Cell Receptor Signaling to Transcriptional Events Required for Early B Cell Expansion. Immunity. 2008;28(4):499-508.
37. Hamel KM, Mandal M, Karki S, Clark MR. Balancing Proliferation with Igκ Recombination during B-lymphopoiesis. Front Immunol. 2014;5:139.
38. Chan LN, Chen Z, Braas D, Lee J-W, Xiao G, Geng H, et al. Metabolic gatekeeper function of B-lymphoid transcription factors. Nature. 2017;542(7642):479-83.
39. Dengler HS, Baracho GV, Omori SA, Bruckner S, Arden KC, Castrillon DH, et al. Distinct functions for the transcription factor Foxo1 at various stages of B cell differentiation. Nat Immunol. 2008;9(12):1388-98.
40. Chow KT, Timblin GA, McWhirter SM, Schlissel MS. MK5 activates Rag transcription via Foxo1 in developing B cells. J Exp Med. 2013;210(8):1621-34.
41. Pelanda R, Schwers S, Sonoda E, Torres RM, Nemazee D, Rajewsky K. Receptor Editing in a Transgenic Mouse Model: Site, Efficiency, and Role in B Cell Tolerance and Antibody Diversification. Immunity. 1997;7(6):765-75.
42. Cheng S, Hsia CY, Feng B, Liou M-L, Fang X, Pandolfi PP, et al. BCR-mediated apoptosis associated with negative selection of immature B cells is selectively dependent on Pten. Cell Res. 2009;19(2):196-207.
43. Katz E, Deehan MR, Seatter S, Lord C, Sturrock RD, Harnett MM. B Cell Receptor-Stimulated Mitochondrial Phospholipase A2 Activation and Resultant Disruption of Mitochondrial Membrane Potential Correlate with the Induction of Apoptosis in WEHI-231 B Cells. J Immunol. 2001;166(1):137-47.
44. Brás A, Ruiz-vela A, González de Buitrago G, Martínez-a C. Caspase activation by BCR cross-linking in immature B cells: differential effects on growth arrest.
and apoptosis. FASEB J. 1999;13(8):931-44.
45. Bouchon A, Krammer PH, Walczak H. Critical role for mitochondria in B cell receptor-mediated apoptosis. Eur J Immunol. 2000;30(1):69-77.
46. Doi T, Motoyama N, Tokunaga A, Watanabe T. Death signals from the B cell antigen receptor target mitochondria, activating necrotic and apoptotic death cascades in a murine B cell line, WEHI-231. Int Immunol. 1999;11(6):933-41.
47. Ly JD, Grubb DR, Lawen A. The mitochondrial membrane potential (ΔΨm) in apoptosis; an update. Apoptosis. 2003;8(2):115-28.
48. Malissey E, Verderi M, Ratinaud MH, Troutaud D. Changes in bad phosphorylation are correlated with BCR-induced apoptosis of WEHI-231 immature B cells. Biochimie. 2003;85(8):733-40.
49. Enders A, Bouillet P, Puthalakath H, Xu Y, Tarlinton DM, Strasser A. Loss of the pro-apoptotic BH3-only Bcl-2 family member Bim inhibits BCR stimulation-induced apoptosis and deletion of autoreactive B cells. J Exp Med. 2003;198(7):1119-26.
50. Kroesen BJ, Pettus B, Luberto C, Busman M, Sietsma H, de Leij L, et al. Induction of apoptosis through B-cell receptor cross-linking occurs via de novo generated C16-ceramide and involves mitochondria. J Biol Chem. 2003;276(17):13606-14.
51. Zeng H, Yu M, Tan H, Li Y, Su W, Shi H, et al. Discrete roles and bifurcation of PTEN signaling and mTORC1-mediated anabolic metabolism underlie IL-7-driven B lymphopoiesis. Sci Adv. 2018;4(1):eaar5701.
52. Carsetti R, Köhler G, Lamers MC. Transitional B cells are the target of negative selection in the B cell compartment. J Exp Med. 1995;181(6):2129-40.
53. Allman D, Pillai S. Peripheral B cell subsets. Curr Opin Immunol. 2008;20(2):149-57.
54. Hayakawa K, Hardy RR, Parks DR, Herzenberg LA. The “Ly-1 B” cell subpopulation in normal immunodefective, and autoimmune mice. J Exp Med. 1983;157(1):202-18.
55. Prieto JMB, Felippe MJB. Development, phenotype, and function of non-conventional B cells. Comp Immunol Microbiol Infect Dis. 2017;54:38-44.
56. Bos NA, Kroese FGM, Cebra JJ. B-1 Cells and the Mucosal Immune System. In: Mucosal Immunology. Amsterdam (The Netherlands): Elsevier; 2005; p. 655-65.
57. Caro-Maldonado A, Wang R, Nichols AG, Kuraoka M, Milasta S, Sun LD, et al. Metabolic Reprogramming Is Required for Antibody Production That Is Suppressed in Anergic but Exaggerated in Chronically BAFF-Exposed B Cells. J Immunol. 2014;192(8):3626-36.
58. Chan LN, Müschen M. B-cell identity as a metabolic barrier against malignant transformation. Exp Hematol. 2017;53:1-6.
59. Pillai S, Cariappa A. The follicular versus marginal zone B lymphocyte cell fate decision. Nat Rev Immunol. 2009;9(11):767-77.
60. Farmer JR, Allard-Chamard H, Sun N, Ahmad M, Bertocchi A, Mahajan VS, et al. Induction of metabolic quiescence defines the transitional to follicular B cell switch. Sci Signal. 2019;12(604):eaaw5573.
61. Sintes J, Gentile M, Zhang S, García-Carmona Y, Magri G, Cassis L, et al. mTOR intersects antibody-inducing signals from TACI in marginal zone B cells. Nat
62. Suzuki H. Xid-Like Immunodeficiency in Mice with Disruption of the p85 Subunit of Phosphoinositide 3-Kinase. Science. 1999;283(5400):390-2.

63. Suzuki H, Matsuda S, Terauchi Y, Fujiwara M, Ohteki T, Asano T, et al. PI3K and Btk differentially regulate B cell antigen receptor-mediated signal transduction. Nat Immunol. 2003;4(3):280-6.

64. Calamito M, Juntilla MM, Thomas M, Northrup DL, Rathmell J, Birnbaum MJ, et al. Akt1 and Akt2 promote peripheral B-cell maturation and survival. Blood. 2010;115(20):4043-50.

65. Iwahashi S, Maekawa Y, Nishida J, Ishifune C, Kitamura A, Arimochi H, et al. Notch2 regulates the development of marginal zone B cells through Fos. Biochem Biophys Res Commun. 2012;418(4):701-7.

66. Saito T, Chiba S, Ichikawa M, Kunisato A, Asai T, Shimizu K, et al. Notch2 is Preferentially Expressed in Mature B Cells and Indispensable for Marginal Zone B Lineage Development. Immunity. 2003;18(5):675-85.

67. Basak N, Banerjee S. Crosstalk between Notch signaling Pathway and Glutamine uptake during Jurkat T cell activation. Matters. 2016. doi: 10.19185/matters.201602000030

68. Gornik O, Pavić T, Lauc G. Alternative glycosylation modulates function of IgG and other proteins—Implications on evolution and disease. Biochim Biophys Acta. 2012;1820(9):1318-26.

69. de Haan N, Falck D, Wuhrer M. Monitoring of immunoglobulin N- and O-glycosylation in health and disease. Glycobiology. 2020;30(4):226-40. doi: 10.1093/glycob/cwz048

70. Hayes JM, Cosgrave EFJ, Struwe WB, Wormald M, Davey GP, Jefferis R, et al. Glycosylation and Fc Receptors. Curr Top Microbiol Immunol. 2014;382:165-99. doi: 10.1007/978-3-319-07911-0_8

71. Gudelj I, Lauc G, Pezer M. Immunoglobulin G glycosylation in aging and diseases. Cell Immunol. 2018;333:65-79.

72. Araujo L, Khim P, Mkhiikian H, Mortales C-L, Demetriou M. Glycolysis and glutaminolysis cooperatively control T cell function by limiting metabolite supply to N-glycosylation. Elife. 2017;6:e21330. doi: 10.7554/eLife.21330

73. Berthe A, Zaffino M, Muller C, Foulquier F, Houdou M, Schulz C, et al. Protein N-glycosylation alteration and glycosylation inhibition both contribute to the antiproliferative action of 2-deoxyglucose in breast cancer cells. Breast Cancer Res Treat. 2018;171(3):581-91.

74. Gauld SB, Benschop RJ, Merrell KT, Cambier JC. Maintenance of B cell anergy requires constant antigen receptor occupancy and signaling. Nat Immunol. 2005;6(11):1160-7.

75. Robin ED, Wong R. Mitochondrial DNA molecules and virtual number of mitochondria per cell in mammalian cells. J Cell Physiol. 1988;136(3):507-13.

76. Wheat W, Kupfer R, Gutches D, Rayat G, Beilke J, Scheiman R, et al. Increased NF-κB activity in B cells and bone marrow-derived dendritic cells from NOD mice. Eur J Immunol. 2004;34(5):1395-404.

77. Salminen A, Hyttinen JMT, Kaarniranta K. AMP-activated protein kinase inhibits NF-κB signaling and inflammation: impact on healthspan and
78. Goldberg IJ. Diabetic Dyslipidemia: Causes and Consequences. J Clin Endocrinol Metab. 2001;86(3):965-71.
79. Mona HM, Sahar SA, Hend SM, Nanees A-WA. Dyslipidemia in type 1 diabetes mellitus: Relation to diabetes duration, glycemic control, body habitus, dietary intake and other epidemiological risk factors. Egypt Pediatr Assoc Gaz. 2015;63(2):63-8.
80. Fahrmann J, Grapov D, Yang J, Hammock B, Fiehn O, Bell GI, et al. Systemic alterations in the metabolome of diabetic NOD mice delineate increased oxidative stress accompanied by reduced inflammation and hypertriglyceremia. Am J Physiol Metab. 2015;308(11):E978-89.
81. Winer DA, Winer S, Shen L, Wadia PP, Yantha J, Paltsier G, et al. B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodies. Nat Med. 2011 May;17(5):610-7.
82. Wilson CS, Elizer SK, Marshall AF, Stocks BT, Moore DJ. Regulation of B lymphocyte responses to Toll-like receptor ligand binding during diabetes prevention in non-obese diabetic (NOD) mice. J Diabetes. 2016;8(1):120-31.
83. Endemann G, Stanton LW, Madden KS, Bryant CM, White RT, Proctor AA. CD36 is a receptor for oxidized low density lipoprotein. J Biol Chem. 1993;268(16):11811-6.
84. Rhoads JP, Major AS. How Oxidized Low-Density Lipoprotein Activates Inflammatory Responses. Crit Rev Immunol. 2018;38(4):333-42.
85. Rhoads JP, Lukens JR, Wilhelm AJ, Moore JL, Mendez-Fernandez Y, Kanneganti T-D, et al. Oxidized Low-Density Lipoprotein Immune Complex Priming of the Nlrp3 Inflammasome Involves TLR and FcγR Cooperation and Is Dependent on CARD9. J Immunol. 2017;198(5):2105-14.
86. Masuda A, Yoshida M, Shiomi H, Morita Y, Kutsumi H, Inokuchi H, et al. Role of Fc Receptors as a therapeutic target. Inflamm Allergy Drug Targets. 2009;8(1):80-6.
87. Ono M, Okada H, Bolland S, Yanagi S, Kurosaki T, Ravetch J V. Deletion of SHIP or SHP-1 Reveals Two Distinct Pathways for Inhibitory Signaling. Cell. 1997;90(2):293-301.
88. Marvin J, Rhoads JP, Major AS. FcγRIIB on CD11c⁺ cells modulates serum cholesterol and triglyceride levels and differentially affects atherosclerosis in male and female Ldlr mice. Atherosclerosis. 2019;285:108-19.
89. Mitchell DM. Growth in patients with type 1 diabetes. Curr Opin Endocrinol Diabetes Obes. 2017;24(1):67-72. doi: 10.1097/MED.0000000000000310
90. Swafford AD-E, Howson JMM, Davison LJ, Wallace C, Smyth DJ, Schuilenburg H, et al. An Allele of IKZF1 (Ikaros) Conferring Susceptibility to Childhood Acute Lymphoblastic Leukemia Protects Against Type 1 Diabetes. Diabetes. 2011;60(3):1041-4.
91. Dufort MJ, Greenbaum CJ, Speake C, Linsley PS. Cell type-specific immune phenotypes predict loss of insulin secretion in new-onset type 1 diabetes. JCI Insight. 2019;4(4):e125556. doi: 10.1172/jci.insight.125556
92. Wu J, Kakoola DN, Lenchik NI, Desiderio DM, Marshall DR, Gerling IC. Molecular Phenotyping of Immune Cells from Young NOD Mice Reveals
Abnormal Metabolic Pathways in the Early Induction Phase of Autoimmune Diabetes. Colombo G, editor. PLoS One. 2012;7(10):e46941.

93. Martins TC, Aguas AP, Involvement of c-myc in the resistance of non-obese diabetic mice to glucocorticoid-induced apoptosis. Immunology. 1998;95(3):377-82.

94. Hulleman E, Kazemier KM, Holleman A, VanderWeele DJ, Rudin CM, Broekhuis MJC, et al. Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells. Blood. 2009;113(9):2014-21.

95. Ehrenstein MR, Cook HT, Neuberger MS. Deficiency in serum immunoglobulin (Ig)M predisposes to development of IgG autoantibodies. J Exp Med. 2000;191(7):1253-8.

96. Colucci M, Stöckmann H, Butera A, Masotti A, Baldassarre A, Giorda E, et al. Sialylation of N-Linked Glycans Influences the Immunomodulatory Effects of IgM on T Cells. J Immunol. 2015;194(1):151-7.

97. Nguyen TTT, Kläsener K, Zürn C, Castillo PA, Brust-Mascher I, Imai DM, et al. The IgM receptor FcμR limits tonic BCR signaling by regulating expression of the IgM BCR. Nat Immunol. 2017;18(3):321-33.

98. Lobo PI, Bajwa A, Schlegel KH, Vengal J, Lee SJ, Huang L, et al. Natural IgM Anti-Leukocyte Autoantibodies Attenuate Excess Inflammation Mediated by Innate and Adaptive Immune Mechanisms Involving Th-17. J Immunol. 2012;188(4):1675-85.

99. Notley CA, Brown MA, Wright GP, Ehrenstein MR. Natural IgM Is Required for Suppression of Inflammatory Arthritis by Apoptotic Cells. J Immunol. 2011;186(8):4967-72.

100. Nguyen TTT, Elsner RA, Baumgarth N. Natural IgM prevents autoimmunity by enforcing B cell central tolerance induction. J Immunol. 2015;194(4):1489-502.

101. Notley CA, Baker N, Ehrenstein MR. Secreted IgM enhances B cell receptor signaling and promotes splenic but impairs peritoneal B cell survival. J Immunol. 2010;184(7):3386-93.

102. Wilson CS, Chhabra P, Marshall AF, Morr C V, Stocks BT, Bonami RH, et al. Healthy Donor Polyclonal IgM's Diminish B Lymphocyte Autoreactivity, Enhance Treg Generation, and Reverse T1D in NOD Mice. Diabetes. 2018;67(11):2349-60. doi: 10.2337/db18-0456

103. Crotzer VL, Matute JD, Arias AA, Zhao H, Quilliam LA, Dinauer MC, et al. Cutting Edge: NADPH Oxidase Modulates MHC Class II Antigen Presentation by B Cells. J Immunol. 2012;189(8):3800-4.

104. Wheeler ML, DeFranco AL. Prolonged Production of Reactive Oxygen Species in Response to B Cell Receptor Stimulation Promotes B Cell Activation and Proliferation. J Immunol. 2012;189(9):4405-16.

105. Östman A, Frijhoff J, Sandin Å, Böhmer F-D. Regulation of protein tyrosine phosphatases by reversible oxidation. J Biochem. 2011;150(4):345-56.

106. Tohyama Y, Takano T, Yamamura H. B Cell Responses to Oxidative Stress. Curr Pharm Des. 2004;10(8):835-9.

107. Wilson CS, Spaeth JM, Karp J, Stocks BT, Hoopes EM, Stein RW, et al. B lymphocytes protect islet β cells in diabetes-prone NOD mice treated with...
108. Feng Y-Y, Tang M, Suzuki M, Gunasekara C, Anbe Y, Hiraoka Y, et al. Essential Role of NADPH Oxidase–Dependent Production of Reactive Oxygen Species in Maintenance of Sustained B Cell Receptor Signaling and B Cell Proliferation. J Immunol. 2019;202(9):2546-57.

109. Bertolotti M, Yim SH, Garcia-Manteiga JM, Macciarelli S, Kim Y-J, Kang M-H, et al. B- to Plasma-Cell Terminal Differentiation Entails Oxidative Stress and Profound Reshaping of the Antioxidant Responses. Antioxid Redox Signal. 2010;13(8):1133-44.

110. Yu X, Lao Y, Teng X-L, Li S, Zhou Y, Wang F, et al. SENP3 maintains the stability and function of regulatory T cells via BACH2 deSUMOylation. Nat Commun. 2018;9(1):3157.

111. Petersone L, Edner NM, Ovcinnikovs V, Heuts F, Ross EM, Ntavli E, et al. T Cell/B Cell Collaboration and Autoimmunity: An Intimate Relationship. Front Immunol. 2018;9:1941.

112. Yarosz EL, Chang C-H. The Role of Reactive Oxygen Species in Regulating T Cell-mediated Immunity and Disease. Immune Netw. 2018;18(1):e14.

113. Kraaij MD, Savage NDL, van der Kooij SW, Koekkoek K, Wang J, van den Berg JM, et al. Induction of regulatory T cells by macrophages is dependent on production of reactive oxygen species. Proc Natl Acad Sci U S A. 2010;107(41):17686-91.

114. Pescovitz MD, Greenbaum CJ, Bundy B, Becker DJ, Gitelman SE, Goland R, et al. B-lymphocyte depletion with rituximab and β-cell function: Two-year results. Diabetes Care. 2014;37(2):453-9.

115. Anolik J, Looney RJ, Bottaro A, Sanz I, Young F. Down-regulation of CD20 on T cells upon CD40 activation. Eur J Immunol. 2003;33(9):2398-409.

116. Elgueta R, Benson MJ, de Vries VC, Wasiuk A, Guo Y, Noelle RJ. Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev. 2009;229(1):152-72.

117. Louvet C, Szot GL, Lang J, Lee MR, Martinier N, Bollag G, et al. Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice. Proc Natl Acad Sci U S A. 2008;105(48):18895-900.

118. Xia CQ, Zhang P, Li S, Yuan L, Xia T, Xie C, et al. C-Abl inhibitor imatinib enhances insulin production by β cells: C-Abl negatively regulates insulin production via interfering with the expression of NKx2.2 and GLUT-2. PLoS One. 2014;9(5):1-11.

119. Hagerkvist R, Sandler S, Mokhtari D, Welsh N. Amelioration of diabetes by imatinib mesylate (Gleevec(R)): role of Beta-cell NF-kappaB activation and anti-apoptotic preconditioning. FASEB J. 2007;21(2):618-28.

120. Morita S, Villalta SA, Feldman IC, Register AC, Rosenthal W, Hoffmann-Petersen IT, et al. Erratum: Targeting ABL-IRE1α Signaling Spares ER-Stressed Pancreatic β Cells to Reverse Autoimmune Diabetes (Cell Metabolism (2017) 25(4) (883-897.e8) (S1550413117301705) (10.1016/j.cmet.2017.03.018)). Cell Metab. 2017;25(5):1207.

121. Reinke EN, Bera S, Diamond AM. Exposure of chronic myelogenous leukemia cells to imatinib results in the post-transcriptional induction of manganese.
superoxide dismutase. Leuk Lymphoma. 2015;56(4):1096-9.

122. Milojkovic D, Apperley J. Mechanisms of Resistance to Imatinib and Second-Generation Tyrosine Inhibitors in Chronic Myeloid Leukemia. Clin Cancer Res. 2009;15(24):7519-27.

How to cite this article:
Wilson CS, Moore DJ. B cell Metabolism: An Understudied Opportunity to Improve Immune Therapy in Autoimmune Type 1 Diabetes. Immunometabolism. 2020;2(2):e200016. https://doi.org/10.20900/immunometab20200016